# US 2012/0251556 A1 · Combination Immunotherapy for the Treatment of Cancer

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0251556 A1
- Document ID: US20120251556A1
- Status: Published application
- Kind: A1
- Application number: 13/498,570
- Filed: 2010-09-30
- Published: 2012-10-04
- Earliest claimed: 2009-09-30
- Assignees: Board of Regents, The University of Texas System; Memorial Sloan Kettering Cancer Center
- Inventors: James Allison; Padmanee Sharma; Sergio A. Quezada; Tihui Fu
- Web page: https://patentgrep.com/patent/US20120251556A1

## CPC

- C07K 16/2818: {against CD28 or CD152}
- A61K 38/1709: {from mammals}
- A61K 39/3955: {against proteinaceous materials, e.g. enzymes, hormones, lymphokines}
- A61K 39/39558: {against tumor tissues, cells, antigens}
- A61P 35/00: Antineoplastic agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 16/2803: {against the immunoglobulin superfamily}
- C07K 16/2827: {against B7 molecules, e.g. CD80, CD86}
- A61K 2039/505: {comprising antibodies}
- A61K 2039/507: {Comprising a combination of two or more separate antibodies}
- C07K 2317/73: Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K 2317/74: Inducing cell proliferation
- C07K 2317/75: Agonist effect on antigen
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Agonists to ICOS in combination with a blocking agent to a T cell inhibitory receptor (e.g., CTLA-4, PD-I, etc.) are demonstrated herein to be useful for the treatment of tumors.

## Claims

### Claim 1

A method of treating cancer in a patient comprising administering to the patient simultaneously or sequentially a composition comprising a blocking agent to a T cell inhibitory receptor and an agonist to ICOS.

### Claim 2 (depends on 1)

The method of claim 1, wherein the blocking agent to a T cell inhibitory receptor is selected from the group consisting of a blocking anti-CTLA-4 antibody, a blocking anti-PD-1 antibody, and a combination thereof.

### Claim 3 (depends on 1, 2)

The method of claim 1 or claim 2, wherein the agonist to ICOS is an anti-ICOS antibody.

### Claim 4 (depends on 1, 2)

The method of claim 1 or claim 2, wherein the agonist to ICOS is ICOS ligand.

### Claim 5 (depends on 4)

The method of claim 4, wherein the ICOS ligand is soluble.

### Claim 6 (depends on 4)

The method of claim 4, wherein the ICOS ligand is expressed on the surface of a cell.

### Claim 7 (depends on 6)

The method of claim 6, wherein the cell is a tumor cell.

### Claim 8 (depends on 7)

The method of claim 7, wherein the tumor cell is irradiated.

### Claim 9 (depends on 7)

The method of claim 7, wherein the tumor cell was surgically removed from the patient.
